Dr. Jared Weiss, MD
Claim this profileLineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill
Studies Lung Cancer
Studies Squamous Cell Carcinoma
16 reported clinical trials
34 drugs studied
Area of expertise
1Lung Cancer
RET positive
Stage IV
Stage III
2Squamous Cell Carcinoma
Stage IV
Stage III
HPV16 positive
Affiliated Hospitals
Clinical Trials Jared Weiss, MD is currently running
CAR T-Cell Therapy
for Lung Cancer
This is a phase 1, single-center, open-label study that enrolls adult subjects with extensive stage lung cancer or stage IV non-small cell lung cancer that is platinum-refractory and received PD-1 and/or PD-L1 therapy. The purpose of this study is to test the safety of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the GD2 antigen (iC9-GD2.CAR.IL-15 T cells) in subjects with lung cancer. How much (dose) of the iC9-GD2.CAR.IL-15 T cells are safe to use without causing too many side effects and what is the maximum dose that could be tolerated will be studied. Modified immune cells as an experimental treatment that combines antibodies and T cells will be used. Antibodies are proteins that protect the body from foreign invaders like bacteria. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill viruses and other cells, including tumor cells. Although antibodies and T cells have been used to treat cancer and they both have shown promise, neither alone has been able to cure most patients. This study will combine T cells and antibodies to create a more effective treatment. The treatment that is being researched in this study is called autologous T lymphocyte chimeric antigen receptor cells targeted against the disialoganglioside (GD2) antigen that expresses Interleukin (IL)-15, and the inducible caspase 9 safety switch (iC9). The short name for this treatment is iC9.GD2.CAR.IL-15 T cells therapy is an experimental therapy and has not been approved by the Food and Drug Administration. There are two steps. In the first step, blood will be collected from the subjects to prepare the iC9-GD2.CAR.IL-15 T cells. T cells will be isolated from the blood and modified to make iC9-GD2.CAR.IL-15. In the second step, the iC9-GD2.CAR.IL-15 T cells produced from the subject's own blood will be administered to the subject.
Recruiting1 award Phase < 16 criteria
Cell Therapy
for Relapsed/Refractory Head and Neck Cancer
The purpose of this study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the CSPG4 antigen (iC9.CAR-CSPG4 T cells) in patients with head and neck cancer that came back after receiving standard therapy for this cancer. The iC9.CAR-CSPG4 treatment is experimental and has not been approved by the Food and Drug Administration. How many (dose) of the iC9.CAR. CSPG4 T cells are safe to use in patients without causing too many side effects, and what is the maximum dose that could be tolerated will be investigated. The information collected from the study would help cancer patients in the future. There are two parts to this study. In part 1, blood will be collected to prepare the iC9.CAR-CSPG4 T cells. Disease fighting T cells will be isolated and modified to prepare the iC9.CAR-CSPG4 T cells. In part 2, the iC9.CAR-CSPG4 T cells are given by infusion after completion of lymphodepletion chemotherapy. The data from the dose escalation will be used to determine a recommended phase 2 dose (RP2D), which will be decided based on the maximum tolerated dose (MTD). Additionally, recommended phase 2 dose will be tested. Eligible subjects will receive lymphodepletion chemotherapy standard followed by infusion of iC9-CAR.CSPG4 T cells. After treatment completion or discontinuation, subjects will be followed since involving gene transfer experiments.
Recruiting1 award Phase 1 & 24 criteria
More about Jared Weiss, MD
Clinical Trial Related4 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Jared Weiss, MD has experience with
- Durvalumab
- Pembrolizumab
- Carboplatin
- Cisplatin
- Lurbinectedin
- Trilaciclib
Breakdown of trials Jared Weiss, MD has run
Lung Cancer
Squamous Cell Carcinoma
Head and Neck Cancers
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jared Weiss, MD specialize in?
Jared Weiss, MD focuses on Lung Cancer and Squamous Cell Carcinoma. In particular, much of their work with Lung Cancer has involved RET positive patients, or patients who are Stage IV.
Is Jared Weiss, MD currently recruiting for clinical trials?
Yes, Jared Weiss, MD is currently recruiting for 5 clinical trials in Chapel Hill North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Jared Weiss, MD has studied deeply?
Yes, Jared Weiss, MD has studied treatments such as Durvalumab, Pembrolizumab, Carboplatin.
What is the best way to schedule an appointment with Jared Weiss, MD?
Apply for one of the trials that Jared Weiss, MD is conducting.
What is the office address of Jared Weiss, MD?
The office of Jared Weiss, MD is located at: Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill, North Carolina 27599 United States. This is the address for their practice at the Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.